Research and development of vaccines

IATI Identifier: NO-BRC-917687811-CEPI_01
Published on IATI IATI
  • date_range Aug 30, 2016
  • autorenew Implementation (Status)

CEPI 1.0 CEPI’s mission is to stimulate and accelerate the development of vaccines against emerging infectious diseases and enable access to these vaccines for people during outbreaks. The budget presented in this activity includes all investments + operating expenses and financial costs. • CFP1 on priority pathogens for EIDs: Launched January 2017 for the diseases Lassa, Nipah and MERS. The decision on priority diseases departed from pathogens identified by the WHO Blueprint for Action, followed by an in-depth assessment by the SAC. In recommending priority diseases to the CEPI Board, the SAC applied criteria related to 1) public health impact (potential of outbreak, transmissibility, burden of disease) and 2) feasibility (current scientific knowledge, pipeline candidates available). • CFP2 on platform technologies: Launched October 2017 to enable rapid vaccine development against both known and unknown pathogens that trigger infections with epidemic potential. A requirement is to produce sufficient vaccine doses to impact an emerging outbreak and that the platform demonstrates versatility one of the priority pathogens from the WHO Blueprint list. • CEPI’s third call for proposals (CfP3i) was for the development of human vaccines against Rift Valley fever and Chikungunya diseases. Rift Valley fever disease is included among the WHO R&D Blueprint list of priority pathogens in 2018, while Chikungunya is deemed to present a major public health risk where further R&D is needed. The call for proposals closed on March, 2019. • In addition to the vaccine development projects, CEPI has made several investments within the Enabling Science area, like biological standards and assays, data collection & scientific research, epidemiology and clinical development. • A global consortium is supporting the Government of the Democratic Republic of the Congo (DRC) to introduce a second investigational Ebola vaccine as part of ongoing efforts to contain the outbreak in eastern DRC. The large-scale clinical trial, sponsored by the London School of Hygiene & Tropical Medicine (LSHTM), is designed to help prevent the spread of the epidemic, the second worst in history, beyond the currently affected areas in eastern DRC, and if possible gather crucial information about the effectiveness of the vaccine to be better prepared to fight Ebola in the future. COVID-19 In 2020 CEPI launched a new call for proposals to develop vaccines against novel coronavirus, COVID-19. COVID-19 data is included in a separate IATI activity. CEPI 2.0 A detailed implementation plan for the CEPI strategy for 2022-26 will be developed in 2021, building from an assessment of implications and risks related to the new strategy and will include the updated governance structure, organizational arrangements, and decision-making processes to guide the implementation of the strategy starting in 2022. The forecasted financial needs for the 2022-2026 business cycle are in the range of US$ 3.5 to 4 billion. The forecast in this IATI activity, includes an estimate of the spending until the end of 2026.

more_horiz
Sectors:
  • Infectious disease control error
    Sector code:
    12250 - Infectious disease control
    Sector vocabulary:
    1 - OECD DAC CRS Purpose Codes (5 digit)

Participating Organisations

Organisation Name Organisation Type Organisation Role
Bill & Melinda Gates Foundation Foundation Funding
Wellcome Trust Foundation Funding
The Government of Norway Government Funding
Government of Japan Government Funding
The Government of Belgium Government Funding
Government of Australia Government Funding
The Government of the United Kingdom Government Funding
International AIDS Vaccine Initiative International NGO Implementing
IDT biologica Private Sector Implementing
Inovio Pharmaceuticals Private Sector Implementing
University of Oxford, The Academic, Training and Research Implementing
Themis Bioscience Private Sector Implementing
University of Tokyo Academic, Training and Research Implementing
CureVac Private Sector Implementing
Imperial College Academic, Training and Research Implementing
University of Queensland Academic, Training and Research Implementing
PATH International NGO Implementing
Aurobindo Private Sector Implementing
Public Health Vaccines Private Sector Implementing
Emergent BioSolutions Private Sector Implementing
Colorado State University Academic, Training and Research Implementing
International Vaccines Institute International NGO Implementing
Larissa Other Implementing
Valneva Private Sector Implementing
BNITM Academic, Training and Research Implementing
Brighton Collaboration National NGO Implementing
INRB Local Government Implementing
LSHTM Academic, Training and Research Implementing
MSF France National NGO Implementing
University of Antwerpen Academic, Training and Research Implementing
Epicentre National NGO Implementing
Dalhousie Univesity Academic, Training and Research Implementing
FIND International NGO Implementing
Janssen Private Sector Implementing
NIBSC Other Public Sector Implementing
Tulane University Academic, Training and Research Implementing
CDV Mali Other Public Sector Implementing
University of North-Carolina Academic, Training and Research Implementing
Nigeria NCDC Other Public Sector Implementing
Benin FORS Academic, Training and Research Implementing
Government of Ethiopia Government Funding
European Commission Other Funding
Vulcan Private Sector Funding
Government of Canada Government Funding
The Government of Germany Government Funding
Government of Denmark Government Funding
Government of Finland Government Funding
Government of Indonesia Government Funding
The Government of Netherlands Government Funding
Government of Singapore Government Funding
Government of South Korea Government Funding
Government of Switzerland Government Funding
The Government of Saudi Arabia Government Funding
Taskforce for Global Health National NGO Implementing
University of Queensland Academic, Training and Research Implementing
Wageningen University & Research - Stichting Wageningen Research Academic, Training and Research Implementing
University of Pittsburgh Academic, Training and Research Implementing
Integrum Private Sector Implementing
Robert Koch Institute Academic, Training and Research Implementing
P-95 Private Sector Implementing
United States Agency for International Development Other Public Sector Funding
MERCK Private Sector Implementing
Technical University of Mombasa Academic, Training and Research Implementing
Medicines and Healthcare products Regulatory Agency (MHRA) Other Public Sector Implementing
Universiti Malaya Academic, Training and Research Implementing
Université Gamal Abdel Nasser de Conakry Academic, Training and Research Implementing
Connected DMV National NGO Implementing
Zalgen Labs Private Sector Implementing
International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b) Academic, Training and Research Implementing

Transaction

Transaction Value circle Provider circle Receiver Type Date
51,332,968 USD (Valued at Dec 31, 2021) circle Provider N/A circle Receiver N/A Disbursement date_rangeDec 31, 2021
12,745,304 USD (Valued at Nov 30, 2021) circle Provider N/A circle Receiver N/A Disbursement date_rangeNov 30, 2021
72,156 USD (Valued at Nov 30, 2021) circle Government of Ethiopia circle Receiver N/A Incoming Funds date_rangeNov 30, 2021
800,733 USD (Valued at Nov 30, 2021) circle Wellcome Trust circle Receiver N/A Incoming Funds date_rangeNov 30, 2021
7,842,934 USD (Valued at Oct 31, 2021) circle Provider N/A circle Receiver N/A Disbursement date_rangeOct 31, 2021
1,156,470 USD (Valued at Oct 31, 2021) circle Government of Finland circle Receiver N/A Incoming Funds date_rangeOct 31, 2021
4,000,000 USD (Valued at Oct 31, 2021) circle Government of the United States of America circle Receiver N/A Incoming Funds date_rangeOct 31, 2021
1,400,000 USD (Valued at Sep 30, 2021) circle Bill and Melinda Gates Foundation circle Receiver N/A Incoming Funds date_rangeSep 30, 2021
8,563,711 USD (Valued at Sep 30, 2021) circle Provider N/A circle Receiver N/A Disbursement date_rangeSep 30, 2021
12,374,583 USD (Valued at Aug 31, 2021) circle Provider N/A circle Receiver N/A Disbursement date_rangeAug 31, 2021
12,500,000 USD (Valued at Jul 31, 2021) circle Provider N/A circle Receiver N/A Incoming Funds date_rangeJul 31, 2021
6,454,441 USD (Valued at Jul 31, 2021) circle Provider N/A circle Receiver N/A Disbursement date_rangeJul 31, 2021
4,594,676 USD (Valued at Jun 30, 2021) circle All outgoing investments + Operating expenses + Financial cost & tax adj. circle Receiver N/A Disbursement date_rangeJun 30, 2021
12,500,000 USD (Valued at Jun 30, 2021) circle Government of Japan circle Receiver N/A Incoming Funds date_rangeJun 30, 2021
600,000 USD (Valued at Jun 30, 2021) circle Government of Singapore circle Receiver N/A Incoming Funds date_rangeJun 30, 2021
9,329,715 USD (Valued at May 31, 2021) circle Provider N/A circle Receiver N/A Disbursement date_rangeMay 31, 2021
3,481,721 USD (Valued at May 31, 2021) circle Government of Canada circle Receiver N/A Incoming Funds date_rangeMay 31, 2021
18,022,761 USD (Valued at May 31, 2021) circle Bill and Melinda Gates Foundation circle Receiver N/A Incoming Funds date_rangeMay 31, 2021
1,352,720 USD (Valued at May 31, 2021) circle Government of Australia circle Receiver N/A Incoming Funds date_rangeMay 31, 2021
1,000,000 USD (Valued at May 31, 2021) circle Provider N/A circle Receiver N/A Incoming Funds date_rangeMay 31, 2021
2,633,238 USD (Valued at Apr 30, 2021) circle Government of Canada circle Receiver N/A Incoming Funds date_rangeApr 30, 2021
4,819,205 USD (Valued at Apr 30, 2021) circle Provider N/A circle Receiver N/A Disbursement date_rangeApr 30, 2021
43,669,316 USD (Valued at Apr 30, 2021) circle Government of Norway circle Receiver N/A Incoming Funds date_rangeApr 30, 2021
18,460,012 USD (Valued at Mar 31, 2021) circle Provider N/A circle Receiver N/A Disbursement date_rangeMar 31, 2021
24,307,244 USD (Valued at Feb 28, 2021) circle Government of Germany circle Receiver N/A Incoming Funds date_rangeFeb 28, 2021
5,987,082 USD (Valued at Feb 28, 2021) circle Provider N/A circle Receiver N/A Disbursement date_rangeFeb 28, 2021
2,622,459 USD (Valued at Feb 28, 2021) circle Wellcome Trust circle Receiver N/A Incoming Funds date_rangeFeb 28, 2021
3,323,603 USD (Valued at Jan 31, 2021) circle Provider N/A circle Receiver N/A Disbursement date_rangeJan 31, 2021
4,000,000 USD (Valued at Jan 31, 2021) circle United States Agency for International Development circle Receiver N/A Incoming Funds date_rangeJan 31, 2021
3,000,000 USD (Valued at Dec 31, 2020) circle Government of South Korea circle Receiver N/A Incoming Funds date_rangeDec 31, 2020
108,917,225 USD (Valued at Dec 31, 2020) circle All outgoing investments + Operating expenses 2020 circle Receiver N/A Disbursement date_rangeDec 31, 2020
1,000,000 USD (Valued at Dec 31, 2020) circle Vulcan circle Receiver N/A Incoming Funds date_rangeDec 31, 2020
97,273 USD (Valued at Nov 30, 2020) circle Other investors circle Receiver N/A Incoming Funds date_rangeNov 30, 2020
10,662,242 USD (Valued at Sep 30, 2020) circle European Commission circle Receiver N/A Incoming Funds date_rangeSep 30, 2020
2,132,449 USD (Valued at Sep 30, 2020) circle European Commission circle Receiver N/A Incoming Funds date_rangeSep 30, 2020
5,704,000 USD (Valued at Jul 31, 2020) circle Government of Germany circle Receiver N/A Incoming Funds date_rangeJul 31, 2020
25,000,000 USD (Valued at Jul 31, 2020) circle Government of Japan circle Receiver N/A Incoming Funds date_rangeJul 31, 2020
599,984 USD (Valued at Jun 30, 2020) circle Government of Singapore circle Receiver N/A Incoming Funds date_rangeJun 30, 2020
2,096,962 USD (Valued at May 31, 2020) circle Wellcome Trust circle Receiver N/A Incoming Funds date_rangeMay 31, 2020
139 USD (Valued at May 31, 2020) circle Other investors circle Receiver N/A Incoming Funds date_rangeMay 31, 2020
20,000,000 USD (Valued at May 31, 2020) circle Bill and Melinda Gates Foundation circle Receiver N/A Incoming Funds date_rangeMay 31, 2020
60,999,925 USD (Valued at Apr 30, 2020) circle Wellcome Trust circle Receiver N/A Incoming Funds date_rangeApr 30, 2020
11,747,016 USD (Valued at Mar 31, 2020) circle The United Kingdom circle Receiver N/A Incoming Funds date_rangeMar 31, 2020
22,602,275 USD (Valued at Mar 31, 2020) circle Government of Norway circle Receiver N/A Incoming Funds date_rangeMar 31, 2020
15,099 USD (Valued at Jan 31, 2020) circle Wellcome Trust circle Receiver N/A Incoming Funds date_rangeJan 31, 2020
211,902,690 USD (Valued at Dec 31, 2019) circle Provider N/A circle Receiver N/A Incoming Funds date_rangeDec 31, 2019
127,521,245 USD (Valued at Dec 31, 2019) circle Provider N/A circle Receiver N/A Disbursement date_rangeDec 31, 2019
113,339,500 USD (Valued at Dec 31, 2018) circle Provider N/A circle Receiver N/A Incoming Funds date_rangeDec 31, 2018
52,540,625 USD (Valued at Dec 31, 2018) circle Provider N/A circle Receiver N/A Disbursement date_rangeDec 31, 2018
8,066,426 USD (Valued at Dec 31, 2017) circle Provider N/A circle Receiver N/A Disbursement date_rangeDec 31, 2017
82,170,677 USD (Valued at Dec 31, 2017) circle Provider N/A circle Receiver N/A Incoming Funds date_rangeDec 31, 2017

Budget

3,272,754,445 USD
131,300,000 USD (Valued at Dec 31, 2018) date_range Jan 01, 2019 - Dec 31, 2019
254,700,000 USD (Valued at Mar 09, 2020) date_range Jan 01, 2020 - Dec 31, 2020
253,254,486 USD (Valued at Mar 29, 2021) date_range Jan 01, 2021 - Dec 31, 2021
369,891,538 USD (Valued at Mar 29, 2021) date_range Jan 01, 2022 - Dec 31, 2022
437,284,815 USD (Valued at Mar 29, 2021) date_range Jan 01, 2023 - Dec 31, 2023
992,218,540 USD (Valued at Mar 23, 2021) date_range Jan 01, 2024 - Dec 31, 2024
633,880,134 USD (Valued at Mar 23, 2021) date_range Jan 01, 2025 - Dec 31, 2025
200,224,932 USD (Valued at Mar 23, 2021) date_range Jan 01, 2026 - Dec 31, 2026
access_timeUpdated on Apr 22, 2022 10:08:17
View XML file here